.

  FOR IMMEDIATE RELEASE
Contact:  

Robert F. Apple, Chief Operating Officer
InKine Pharmaceutical Company, Inc.
215-283-6850

Donald C. Weinberger
Wolfe Axelrod Weinberger Assoc. LLC
212-370-4500, 212-370-4505 fax
[email protected]


INKINE TO PRESENT AT RODMAN & RENSHAW TECHVEST
HEALTHCARE CONFERENCE

 

BLUE BELL, PA September 25, 2003 -- InKine Pharmaceutical Company, Inc. (Nasdaq: INKP) today announced that it will participate in the Rodman & Renshaw Techvest Healthcare   Conference, to be held October 21 - 23, 2003 at the Marriott Longwharf Hotel in Boston.   Leonard S. Jacob, M.D., Ph.D., Chairman and CEO of InKine, is scheduled to speak at 12:20 PM EDT on October 21, 2003 and is expected to discuss the Company's product opportunities, strategic initiatives and prescription trends .

"I am pleased to have the opportunity to present at the Rodman & Renshaw Healthcare   Conference," said Dr. Jacob,   "We have had several measured successes so far this year and have more to look forward to for the remainder of 2003 and beyond, which I intend to highlight at the Rodman conference.   One such success was the recent attainment of over 8,000 Visicol ® prescriptions per week and a new all-time-high market share, based on our most recent unaudited weekly prescription data," added Dr. Jacob.

About InKine Pharmaceutical
InKine Pharmaceutical Company, Inc. is a publicly traded biopharmaceutical company focused on the diagnosis and treatment of cancer and autoimmune diseases. The Company's development strategy is to acquire late-stage drug candidates with short time lines to commercialization. The Company's first product, Visicol™ is the first and only tablet purgative preparation indicated for bowel cleansing prior to colonoscopy. InKine's second product, IBStat™, is a novel oral hysocyamine spray for the treatment of Irritable Bowel Syndrome (IBS) and spasm of the colon. Additionally, the Company is developing other clinical compounds such as Colirest™, which is in clinical trials for the treatment of Crohn's disease and completed Phase II trials for the treatment of ulcerative colitis. For further information, please visit InKine on their web site http://www.inkine.com.

In addition to historical facts or statement of current condition, this press release may contain forward-looking statements. Forward-looking statements provide InKine's current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, development of potential pharmaceutical products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, sales and earnings projections, and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe" or other words and terms of similar meaning. InKine's performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries as well as more specific risks and uncertainties such as those set forth in its reports on Form 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, InKine does not intend (and it is not obligated) to update publicly any forward-looking statements. This discussion is permitted by the Private Securities Litigation Reform Act of 1995.